Categories
BLOG

cbd dosage for brain tumor

Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature

Affiliations

  • 1 Department of Anaesthesiology and Intensive Care, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
  • 2 Neurological Department, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
  • 3 CIS Clinical Investigation Support GmbH, Vienna, Austria [email protected]
  • PMID: 31570484
  • DOI: 10.21873/anticanres.13783

Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature

  • Search in PubMed
  • Search in NLM Catalog
  • Add to Search

Authors

Affiliations

  • 1 Department of Anaesthesiology and Intensive Care, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
  • 2 Neurological Department, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria.
  • 3 CIS Clinical Investigation Support GmbH, Vienna, Austria [email protected]
  • PMID: 31570484
  • DOI: 10.21873/anticanres.13783

Abstract

Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent years, an increasing number of data from in vitro and in vivo research with cannabinoids, particularly with the non-intoxicating cannabidiol (CBD), point to their potential role as tumour-inhibiting agents. Herein, a total of nine consecutive patients with brain tumours are described as case series; all patients received CBD in a daily dose of 400 mg concomitantly to the standard therapeutic procedure of maximal resection followed by radiochemotherapy. By the time of the submission of this article, all but one patient are still alive with a mean survival time of 22.3 months (range=7-47 months). This is longer than what would have been expected.

Keywords: Cannabidiol; brain tumours; cannabinoids; chemoradiation; glioblastoma multiforme.

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent years, an increasing num … ]]>